1. Managing Polycythemia Vera in the Community Setting

3. Polycythemia Vera Introduction

4. 2016 WHO Diagnostic Criteria for PV Summary of Changes to 2008 Criteria

7. Is BM Biopsy Always Required?

8. Progression of PV Is Genetic Testing Useful At This Time?

9. Prognostic Impact of Next-Generation Sequencing

10. Symptom Burden in Patients With PV

12. Treatment Goals Patient vs Physician

14. Cytoreductive Therapy Hydroxyurea

15. Cytoreductive Therapy Long-Acting IFN-α

16. HCT ≥45% Increases The Risk of CV-Related Death or Thrombosis

17. Management Summary of Patient With PV

19. Resistance or Intolerance to HU in a Study of 890 Patients With PV

20. HU Intolerance in Patients With PV Symptoms and QoL

21. Advantages of Long Acting IFN-α Therapy for PV

22. Ruxolitinib

24. RESPONSE Thromboembolic Adverse Events at Week 80

25. RESPONSE Other Adverse Events of Interest

26. How to Address Adverse Events

27. Concluding Remarks

28. Abbreviations

29. Abbreviations (cont)